Kronox Lab share price & results
- Jun 2026
- Sept 2026
Vadodara (Gujarat)-based manufacturer of high-purity specialty fine chemicals — excipients, reagents and ingredients for pharmaceutical, nutraceutical and food applications.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 28.4 | +16.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 31.7 | −1.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 7.3 | +16.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 27.74 | −4.9 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 20.79 | −7.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 6.07 | −10.1 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +28.6% 1Y
1Y: ₹150.51 on 24 Oct 2025 → ₹193.6. High ₹218.79 (14 Oct 2026), low ₹97.02 (30 Mar 2026).
- Previous close
- ₹184.93
- Market cap
- ₹710 Cr
- 52-week range
- ₹97.02 – ₹218.79
- One year
- +27.36%
- Price to earnings (TTM to Jun 2026)
- 24.85×
- Return on equity (TTM to Jun 2026)
- 27.74%
Overview
- Symbol
- NSE:KRONOX
- Sector
- Chemicals
- Industry
- Commodities
- Exchange
- NSE
- Currency
- INR
What Kronox Lab does
Based on the company's own presentations, annual report and earnings calls.
KRONOX Lab Sciences manufactures high-purity specialty fine chemicals sold as excipients, reagents and ingredients to pharmaceutical, nutraceutical and food industries. It runs three manufacturing units in Padra taluka, Vadodara district, Gujarat, with a combined installed capacity of 7,242 MTPA spread over 1.88 lakh sq.ft. The company has exported these chemicals since 2010 and holds facility certifications including FSSC 22000, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, GMP, GLP, Kosher and Halal. It is also developing a fourth manufacturing unit at Dahej, for which land has been acquired and key statutory approvals obtained.
Segments
- Pharmaceutical & nutraceutical excipients/reagents
- Food grade fine chemicals
- Manufacturing facilities
- 3 (Unit I, II & III, Padra taluka, Vadodara)
- Installed capacity
- 7,242 MTPA
- Cumulative manufacturing area
- 1.88 Lakh sq.ft
- Product portfolio
- ~185 products
- Planned Unit IV land (Dahej)
- 20,471 sq.mtr
- Quality certifications
- FSSC 22000, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, GMP, GLP, Kosher, Halal
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +16% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 24 | 26 | 24 | 26 | 25 | 26 | 28 |
| Expenses | 16 | 16 | 18 | 16 | 17 | 17 | 17 | 19 |
| Operating profit | 9 | 8 | 8 | 8 | 9 | 8 | 10 | 9 |
| Operating margin | 35.4% | 34.8% | 29.7% | 32.8% | 33.9% | 31.8% | 36.4% | 31.7% |
| Other income | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit before tax | 9 | 9 | 8 | 8 | 9 | 9 | 11 | 10 |
| Tax rate | 26.6% | 26.1% | 24.1% | 25.7% | 27.2% | 23.4% | 27.0% | 25.6% |
| Net profit | 6 | 7 | 6 | 6 | 7 | 7 | 8 | 7 |
| EPS (₹ per share) | 1.74 | 1.76 | 1.70 | 1.69 | 1.80 | 1.78 | 2.16 | 1.97 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 90 | 100 | 101 |
| Expenses | 62 | 67 | 67 |
| Operating profit | 28 | 33 | 34 |
| Other income | 2 | 3 | 5 |
| Interest | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 2 |
| Profit before tax | 29 | 34 | 37 |
| Net profit | 21 | 25 | 28 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 37 | 37 | 37 | 37 | 37 |
| Reserves | 40 | 8 | 29 | 53 | 64 | 79 |
| Borrowings | 3 | 0 | 0 | 0 | 3 | 2 |
| Other liabilities | 13 | 9 | 8 | 9 | 9 | 10 |
| Total liabilities | 57 | 54 | 74 | 99 | 113 | 128 |
| Fixed assets | 11 | 16 | 26 | 28 | 30 | 29 |
| Capital work in progress | 0 | 0 | 0 | 1 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 45 | 38 | 47 | 70 | 82 | 98 |
| Total assets | 57 | 54 | 74 | 99 | 113 | 128 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 11 | 9 | 20 | 17 | 31 | 24 |
| Cash from investing | -3 | -8 | -7 | -17 | -28 | -24 |
| Cash from financing | -7 | -1 | -13 | 0 | -2 | 0 |
| Net cash flow | 1 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | 10 | 5 | 11 | 5 | 28 | 21 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 90 | 114 | 71 | 72 | 72 | 76 |
| Inventory days | 58 | 58 | 61 | 74 | 47 | 66 |
| Days payable | 69 | 89 | 52 | 51 | 54 | 52 |
| Cash conversion cycle | 79 | 84 | 80 | 94 | 66 | 90 |
| Working capital days | 95 | 122 | 83 | 143 | 65 | 71 |
| Return on capital employed | 50.0% | 51.0% | 50.0% | 52.0% | 44.0% | 36.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 9.0% | 7.0% | 7.0% |
What the price assumes
ExpensiveTo justify its price of ₹194, this stock must grow earnings at 18% every year for 7 years. Our analysis caps realistic growth at ~14%. At that growth it is worth ₹152 — downside of 21%.
- Growth the price implies
- 18.3% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 13.6% a year
- net profit, FY24–FY26 · EPS 13.7%
- The gap
- 0.0 pp
- -21% downside if it only repeats history
Ownership
Who owns it
Promoters hold 64.26% as of Sept 2026; institutions added 0.53 pts since Jun 2026.
- Promoters 64.26%
- Foreign institutions 0.10%
- Domestic institutions 2.54%
- Public 33.11%
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 64.26% held
- AIF +0.81 pp 2.52% held
The same filing shows 0 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Kronox Lab above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 64.26% | newly disclosed | |
| AIF | 2.52% | +0.81 pp |
| — | off the list | |
| — | off the list | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Kronox Lab
Free account: one company. Everything above stays public.
Write why you follow Kronox Lab and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Chemicals companies
Learn to analyse Kronox Lab
Guides on how to read this kind of business and the numbers that matter.